abstract |
The present invention discloses a GPR119 agonist, with a structural formula shown in a general formula (I). The present invention also provides methods for treating diseases with GPR119 as a treatment target, by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound; and method for treating or preventing metabolic disorders and obesity by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound. |